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Tacrolimus Toxicity Associated with 
Concomitant Metoclopramide Therapy
William A. Prescott, Jr., Pharm.D., Brian L. Callahan, Pharm.D., 
and Jeong M. Park, Pharm.D., M.S.
Subtherapeutic tacrolimus trough concentrations were noted in a 52-year-old
woman who had undergone liver transplantation.  Her tacrolimus dosage was
increased from 7 to 28 mg twice/day, and ketoconazole therapy was added;
however, her tacrolimus concentration remained undetectable.
Metoclopramide 10 mg 4 times/day was begun to control the patient’s new-
onset nausea and vomiting.  Within 48 hours of increasing the dosage to 20
mg 4 times/day, her tacrolimus trough concentration exceeded 30 ng/ml.
Signs and symptoms were suggestive of tacrolimus nephrotoxicity and
neurotoxicity.  According to the Naranjo scale, this adverse drug event was
probably the result of improved absorption of tacrolimus secondary to
metoclopramide therapy.  The patient’s subtherapeutic tacrolimus
concentration at baseline was probably secondary to poor absorption due to
impaired gastric emptying.  Coadministration of metoclopramide significantly
improved gastric motility and delivery of tacrolimus to the small intestine,
increasing tacrolimus bioavailability, thus resulting in acute-onset tacrolimus
toxicity.  When tacrolimus is administered with metoclopramide in patients
with gastric dysmotility, tacrolimus concentrations should be monitored
closely to minimize the risk of toxicity.
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Tacrolimus, a macrolide with potent immuno-
suppressive properties, is approved by the Food
and Drug Administration for prophylaxis against
rejection after liver and kidney transplantation.
Tacrolimus absorption, like cyclosporine absorp-
tion, is variable, incomplete, and dependent on
proper gastric motility.1, 2 Metoclopramide, a
prokinetic agent commonly administered to treat
gastric dysmotility, accelerates gastric emptying
and intestinal transit.3 The manufacturer of
tacrolimus reports that due to effects on gastric
motility, metoclopramide may increase the
bioavailability of tacrolimus.1 Concomitant
administration of these two agents thus may
increase whole blood tacrolimus concentration
and the risk of toxicity.  However, documentation
of such an interaction between metoclopramide
and tacrolimus remains poor.  We describe the
first case report, to our knowledge, of a clinically
significant pharmacodynamic interaction
between these two drugs.
Case Report
A 52-year-old, 91-kg woman with a history of
end-stage liver disease secondary to primary
biliary cirrhosis underwent liver transplantation
approximately 11.5 years ago.  About 7 years
later, a liver biopsy showed chronic rejection, and
the patient’s therapy was changed from
cyclosporine to tacrolimus.  The patient received
tacrolimus and prednisone for maintenance
therapy for about 3 years; at that time, sirolimus
was added to her immunosuppressant regimen.
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Her tacrolimus trough concentrations generally
remained within the therapeutic goal range (5–10
ng/ml), ranging from 4.2–8.9 ng/ml in the 2
months preceding the onset of subtherapeutic
tacrolimus concentrations.
About 6 months later, a tacrolimus trough level
obtained on an outpatient basis revealed a
concentration less than 2 ng/ml, which was
below the lower limit of detection of our assay
(Table 1).  At that time she was taking ursodiol
600 mg twice/day, pantoprazole 40 mg once/day,
and alendronate 70 mg once/week in addition to
her immunosuppressant regimen, which consisted
of prednisone 15 mg once/day, tacrolimus 7 mg
twice/day, and sirolimus 4 mg once/day.  Of note,
she had been receiving the same dosage of
tacrolimus and sirolimus for at least 2 months
preceding the onset of subtherapeutic tacrolimus
levels.
Two weeks after the patient’s tacrolimus trough
level was obtained, her dosage was increased to
14 mg twice/day.  Despite this significant
increase, her tacrolimus trough concentration
remained undetectable.  She was admitted to the
hospital 10 days later with a tacrolimus trough
level below 2 ng/ml and a 1-week history of
increased jaundice, itching, and thirst, which are
symptoms suggestive of acute graft rejection.
Her alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels on
admission were 240 and 228 IU/L, respectively,
elevated from baseline levels of 100–200 IU/L
(normal ranges 0–45 IU/L [ALT], 2–35 IU/L
[AST]).  She reported dry heaves, but her
appetite was unchanged.  On the day of her
admission, a 3-day course of intravenous
methylprednisolone 60 mg followed by a
prednisone taper was added to treat the rejection
empirically.  On day 5, her subtherapeutic drug
concentrations persisted, and her tacrolimus
dosage was increased to 28 mg twice/day.
On day 6, rifampin 300 mg twice/day was
added to control the patient’s pruritic symptoms.
After a pharmacy consultation on day 9, rifampin
was discontinued.  Because rifampin induces
cytochrome P450 (CYP) 3A4, it may have been
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Table 1.  Correlation Between Concomitant Drugs Administered with Tacrolimus and Whole Blood
Tacrolimus Concentrations
Tacrolimus
Concentration Tacrolimus
Date (ng/ml) Dosage Concomitant Drugs Administered
11-18-02 < 2.0 7 mg b.i.d. Sirolimus 4 mg q.d.
12-2-02 < 2.0 14 mg b.i.d.
12-10-02 < 2.0
12-14-02 < 2.0
12-15-02 Sirolimus increased to 7.5 mg b.i.d.
12-17-02 < 2.0 28 mg b.i.d.
12-18-02 < 2.0 Rifampin 300 mg b.i.d. started
12-20-02 < 2.0
12-21-02 < 2.0 Rifampin discontinued.
12-22-02 < 2.0 Cimetidine 400 mg q.d. started.
12-23-02 < 2.0 Cimetidine discontinued,
ketoconazole 200 mg q.d. started.
12-24-02 < 2.0
12-27-02 < 2.0 Metoclopramide 10 mg q.i.d. started.
12-30-02 < 2.0
12-31-02 < 2.0 Metoclopramide increased to 20 mg q.i.d.
1-01-03 5.6
1-02-03 > 30 20 mg b.i.d.
1-04-03 > 30 Discontinued
1-05-02 > 30 Sirolimus and ketoconazole discontinued.
1-06-03 24.9
1-07-03 14.3 4 mg b.i.d.
1-11-03 10.5 Metoclopramide 10 mg b.i.d. restarted.
1-24-03 10.5 4 mg in A.M.,
3 mg in P.M.
2-26-03 Metoclopramide discontinued.
3-04-03 11.8
5-07-03 12.4 3 mg b.i.d.
5-16-03 8.9 2 mg b.i.d.
5-17-03 6.8 1 mg b.i.d.
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hindering efforts to attain a therapeutic
tacrolimus concentration.  Oral cimetidine 400
mg once/day was added on day 10 for its
CYP3A4-inhibiting properties in an attempt to
increase the patient’s tacrolimus blood concen-
tration.  The next day, cimetidine was discontinued
in favor of ketoconazole 200 mg once/day, as
ketoconazole may be a more potent inhibitor of
CYP3A4.
Inadequate immunosuppression was a concern;
thus, mycophenolate mofetil was added to her
regimen on day 11 before an adequate trial with
ketoconazole.  On day 14, the patient had a low-
grade fever and complained of new-onset nausea
and vomiting with any oral intake.  To control
her symptoms, metoclopramide 10 mg 4
times/day was started.  An esophagogastro-
duodenoscopy conducted on day 18 did not
reveal any physiologic cause for her nausea and
vomiting.  Ondansetron 4 mg 4 times/day was
added, and her metoclopramide dosage was
increased to 20 mg 4 times/day on day 19.  After
this her nausea and vomiting improved.
During this hospital stay the patient was also
treated with ursodiol, levofloxacin, metronidazole,
ranitidine, omeprazole, and pantoprazole, none
of which seemed to have a definite effect on her
tacrolimus concentrations.  She was discharged
to home on day 20, with a regimen of tacrolimus
28 mg twice/day, sirolimus 7.5 mg twice/day,
mycophenolate mofetil 500 mg twice/day,
prednisone 60 mg once/day, ursodiol 600 mg
twice/day, ketoconazole 200 mg once/day,
omeprazole 20 mg twice/day, ondansetron 4 mg
every 8 hours, and metoclopramide 20 mg before
meals and at bedtime.
On the day of the patient’s discharge, her
tacrolimus trough concentration was 5.6 ng/ml.
A tacrolimus trough concentration obtained on
an outpatient basis the next day revealed a
supratherapeutic level greater than 30 ng/ml,
which is the upper limit of detection for our
assay.  The patient’s tacrolimus dosage was
decreased to 20 mg twice/day.  Two days later, she
came to the emergency department with
complaints of tremor, weakness, headache, leg
pain, and nausea and vomiting.  She also
reported a 2-day history of diarrhea, which had
worsened progressively.
Elevated blood urea nitrogen and serum
creatinine levels of 58 and 3.3 mg/dl, respectively,
from baseline values of 20 and 1.1 mg/dl,
respectively, indicated that the patient was
experiencing acute renal failure.  Fractional
excretion of sodium was equal to 3.79% (normal
< 2.0%), suggesting acute tubular necrosis, which
may have been indirectly related to tacrolimus
toxicity.  Her ALT and AST levels, although
elevated at 190 and 144 IU/L, respectively, were
not significantly increased from baseline.
Ketoconazole was discontinued on readmission
to the hospital, and tacrolimus was temporarily
withheld.
On day 2 after the patient’s readmission,
sirolimus and mycophenolate mofetil were
discontinued given the high degree of immuno-
suppression she experienced with supratherapeutic
tacrolimus levels.  Metoclopramide, ondansetron,
and pantoprazole were continued throughout
this hospital stay.  Tacrolimus levels greater than
30 ng/ml persisted for 2 days, when they began
to trend downward.  The patient’s renal function
improved as her tacrolimus concentration
decreased.  Liver function tests remained stable
throughout her 4-day hospital stay.
On day 4, tacrolimus 4 mg twice/day was
restarted; the goal was to maintain blood levels of
5–10 ng/ml.  Seventeen days later, tacrolimus was
decreased from 4 mg twice/day to 4 mg in the
morning and 3 mg in the evening.  About 2
weeks earlier, metoclopramide had been
decreased to 10 mg twice/day; about 4 weeks
after that, metoclopramide therapy was
discontinued due to concern that it may be
contributing to her hand tremor.
About 4 months later, the patient was receiving
tacrolimus 1 mg twice/day, and her whole blood
trough concentration was stable at 6.8 ng/ml.
This dosage was 14% of the original dosage
(tacrolimus 7 mg twice/day) that she had taken
for maintenance during the months preceding
the initial hospitalization.  The reason she could
maintain a therapeutic tacrolimus concentration
with the lower dosage remains undetermined.
Discussion
Our patient was treated for suspected gastric
dysmotility with metoclopramide, which resulted
in a significant increase in tacrolimus blood
concentration and acute-onset tacrolimus
toxicity.  A Naranjo score of 5 was calculated,4
suggesting that our patient’s tacrolimus toxicity
was secondary to a probable pharmacodynamic
interaction between metoclopramide and
tacrolimus.
The significant interindividual and intraindividual
pharmacokinetic and pharmacodynamic varia-
bility, along with the narrow therapeutic index of
tacrolimus, necessitates routine monitoring of
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whole blood drug concentrations.  Therapeutic
goal trough concentrations generally range from
5–20 ng/ml.  The specific target concentration
may vary depending on time since transplantation
and on the protocol of the transplant center.
For our patient, who had undergone liver
transplantation more than 10 years ago, the
target tacrolimus trough concentration was 5–10
ng/ml according to the transplant center
protocol.  Subtherapeutic concentrations may
ultimately result in graft rejection, whereas
supratherapeutic concentrations have been
associated with tacrolimus toxicity.5–10 Both
inpatient and outpatient tacrolimus levels in our
patient were performed at the hospital by means
of microparticle enzyme immunoassay, which has
a detection range of 2–30 ng/ml.  All inpatient
tacrolimus concentrations were drawn as trough
levels according to hospital procedure.  Whether
outpatient tacrolimus concentrations were drawn
as trough levels could not be definitively
confirmed.
Nephrotoxicity and neurotoxicity are common
adverse events seen with elevated tacrolimus
concentrations.5, 7, 8, 10 Generally, the symptoms
associated with elevated tacrolimus levels are
reversible if the tacrolimus regimen is
appropriately modified.6 Our patient had
complained of headache, tremor, and weakness,
which are common manifestations of tacrolimus-
associated neurotoxicity.  Elevated blood urea
nitrogen and serum creatinine levels indicated
that the patient was experiencing acute renal
failure.  Other potential causes were ruled out,
suggesting that the patient’s renal dysfunction
was due to acute tubular necrosis, which may
have been precipitated by her high tacrolimus
concentration.
Since CYP3A4 is the primary isoenzyme
responsible for tacrolimus metabolism, clinically
relevant drug interactions can occur when agents
that inhibit or induce this isoenzyme are
administered concomitantly.  Inhibition of
tacrolimus metabolism by agents such as
ketoconazole may result in an increased risk for
nephrotoxicity and neurotoxicity.11–14 Induction
of CYP3A4 by agents such as rifampin leads to
reduced tacrolimus bioavailability and a higher
rate of clearance, ultimately resulting in
subtherapeutic levels and impaired efficacy.14–18
Although the onset of enzyme inhibition is
rapid, enzyme induction is a slow, time-
dependent process.11 The onset of clinically
significant elevations in whole blood tacrolimus
concentrations in ketoconazole-treated patients
may be noted as soon as 1 day after the start of
therapy, whereas rifampin may not exert a
clinically significant effect on concentration until
2–12 days of therapy.14, 16, 18
The subtherapeutic tacrolimus trough concen-
trations in our patient probably were not the
result of extensive intrinsic metabolic clearance.
If enhanced metabolism had been the cause, the
addition of ketoconazole, which would have
rapidly caused CYP3A4 inhibition, would have
resulted in a prompt increase in tacrolimus
concentration.  However, the patient’s tacrolimus
levels remained subtherapeutic for 10 days after
the start of ketoconazole therapy.  It seems
unlikely that this treatment resulted in a delayed-
onset inhibition of CYP3A4.  Metoclopramide
inhibits CYP2D6 but has no known effect on
CYP3A4; therefore, a drug interaction with
tacrolimus is unlikely to occur by way of this
mechanism.3
Rifampin was added to the patient’s drug
regimen on day 6 after her hospital admission
even though this agent lowers whole blood
tacrolimus concentrations.14–18 Thus, the
rifampin might have induced the CYP3A4
enzyme system, potentially impairing the ability
of ketoconazole to inhibit this isoenzyme
adequately and increase tacrolimus levels.
However, one published case report suggested
that after discontinuing rifampin after 4 days of
therapy, enzyme induction and accelerated
tacrolimus metabolism dissipated within 6 days.14
Our patient was treated with rifampin for only
3 days; rifampin was discontinued 2 days before
ketoconazole therapy was begun, and no increase
in tacrolimus levels occurred for 9 additional
days.  Thus, it is unlikely that rifampin had any
clinically significant effect on impairing or
delaying the ability of ketoconazole to exert its
inhibition of CYP3A4.  If it had, given the rapid
nature of ketoconazole enzyme inhibition, the
patient’s tacrolimus concentration would likely
have increased much sooner after rifampin
discontinuation.  Thus, it is also unlikely that
ketoconazole itself was the underlying cause of
the patient’s tacrolimus toxicity because, as
mentioned, the effect on tacrolimus would have
been observed much earlier than it was.14
Sirolimus at doses of 2 mg and above has been
shown to reduce the area under the concentration-
time curve (AUC) of tacrolimus when administered
concomitantly.19 Tacrolimus and sirolimus, in
stable doses, were administered concomitantly
for several months before the onset of the
subtherapeutic tacrolimus concentrations, and
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therapy with sirolimus was continued through
the onset of supratherapeutic tacrolimus levels.
A similar effect of sirolimus on tacrolimus concen-
trations was not observed in our patient; thus, the
changes in tacrolimus concentrations probably
were not due to an interaction with sirolimus.
The bioavailability of orally administered
tacrolimus is generally poor and erratic,
averaging about 25% and ranging from 4–89%.3
This is likely due to extensive first-pass
metabolism in the intestine and liver as well as
variability in the intestinal and hepatic contents
of CYP3A4 and P-glycoprotein.20, 21 In addition,
the rate and extent of tacrolimus absorption have
decreased when tacrolimus was administered
with food, especially a meal high in fat, by
delaying gastric emptying.22, 23 The impaired
tacrolimus absorption seen in certain patient
populations thus may be the result of alterations
in gastric motility.5 This was speculated to be the
underlying etiology of our patient’s persistent
subtherapeutic tacrolimus concentrations.
Cyclosporine, like tacrolimus, is absorbed
predominantly in the small intestine.  Absorption
of these immunosuppressants is thus dependent
on proper gastric emptying.  One study assessed
the effect of coadministered oral metoclopramide
on the absorption of oral cyclosporine 4–10
mg/kg/day (mean 7.5 mg/kg/day) in 14 patients
who underwent kidney transplantation.2 When
metoclopramide was added to the cyclosporine
regimen, the area under the concentration-time
curve of cyclosporine increased by 29%
(p=0.003), and cyclosporine peak concentration
increased in 22 of 24 patients studied (p=0.00005).
In addition, the time to reach peak concen-
tration significantly decreased with concurrent
metoclopramide therapy (p=0.01), indicating an
increase in the rate of cyclosporine absorption.
The authors concluded that the addition of
metoclopramide significantly increased the rate
and extent of cyclosporine absorption, and that
this effect was the result of enhanced gastric
emptying of cyclosporine.
Our patient’s subtherapeutic tacrolimus
concentrations apparently were secondary to
poor absorption due to impaired gastric
emptying.  As an outpatient, her compliance with
her drug regimen was unknown but was thought
to be acceptable.  In addition, given that her
tacrolimus levels remained subtherapeutic
throughout her prolonged hospital stay, poor
compliance does not appear to have been a
contributing factor.  The large tacrolimus dosage
she received would have been expected to
produce supratherapeutic concentrations if her
gastrointestinal tract was working properly,
especially in the presence of a potent enzyme
inhibitor such as ketoconazole.
The patient’s tacrolimus trough concentration
began to trend upward 5 days after meto-
clopramide therapy was started and 1 day after
the dosage was increased from 10 to 20 mg 4
times/day.  The lower dosage of metoclopramide
given initially did not appear to improve the
patient’s gastrointestinal symptoms, whereas the
higher dosage was effective.  Thus, it is not
surprising that the tacrolimus concentration did
not improve until the metoclopramide dosage
was increased.  After that, the patient’s tacrolimus
concentration increased, an effect believed to
have resulted from optimal gastric emptying.
Ketoconazole may have significantly impaired
the first-pass metabolism of tacrolimus once the
drug was delivered properly to its absorption site,
further contributing to our patient’s supra-
therapeutic tacrolimus concentrations.  Diarrhea
also causes elevations in tacrolimus levels.24, 25
However, our patient’s diarrhea seemed to occur
after her tacrolimus levels became elevated and
was thus more likely an adverse event secondary
to the high levels than a cause of the toxicity.
Her diarrhea, however, may have further elevated
her already toxic tacrolimus concentration.
Although the dramatic changes in our patient’s
whole blood tacrolimus concentration could be
confounded by several variables, the primary
cause of her elevated levels appears to have been
metoclopramide.  One could argue that since
removing metoclopramide from her drug regimen
approximately 2 months after it was started did
not result in recurrence of subtherapeutic
tacrolimus levels, metoclopramide might not
have been the causative agent.  When it was
discontinued, however, an indication for therapy
no longer existed.  Hence, the patient’s earlier
gastric dysmotility had improved and no longer
impaired absorption of tacrolimus.
Conclusion
Coadministration of metoclopramide with
tacrolimus in our patient resulted in significantly
elevated whole blood tacrolimus concentration,
probably because this therapy improved the
patient’s gastric motility.  When metoclopramide
is added to tacrolimus therapy in patients with
gastric dysmotility, tacrolimus concentrations
should be monitored closely to avoid tacrolimus
toxicity.
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